Related Experiment Video
Updated: Jan 7, 2026
Behavioral And Physiological Analysis In A Zebrafish Model Of Epilepsy
Published on: October 19, 2021
Behavioral and epileptic phenotypes in a CHD2-related developmental delay model
Anat Mavashov1,2, Shaked Turk1,2, Yael Sarusi3,4
1Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Goldschleger Eye Research Institute, Tel Aviv University, Tel Aviv, Israel.
Objective:
Heterozygous loss-of-function mutations in the CHD2 gene, encoding chromodomain helicase DNA-binding protein 2, are associated with severe childhood onset epilepsy, global developmental delay, and autistic features. Animal models that accurately recapitulate human phenotypes are crucial for understanding rare neurodevelopmental disorders and developing novel treatments. However, such a model for CHD2-related disorders has been missing.
Methods:
We performed behavioral, electrographic, epileptic, and transcriptomic analyses to characterize a mouse model harboring a frameshift truncating mutation in the Chd2 gene (Chd2WT/m and Chd2m/m mice) on the 129X1/SvJ background.
Results:
The genetic background altered the severity of disease-related phenotypes, such that crossing the mice from the C57BL/6J onto the 129X1/SvJ background uncovered neurodevelopmental phenotypes. On the 129X1/SvJ background, Chd2m/m mice exhibited growth retardation, and both Chd2WT/m and Chd2m/m mice showed motor deficits, including clasping behavior and impaired balance on a rotating rod. Autistic like features included reduced nest-building abilities in Chd2m/m mice, whereas increased repetitive like behavior in the marble-burying test and altered social behavior were observed in Chd2WT/m mice. Electrocorticographic analysis revealed a global reduction in the power of background oscillations in both Chd2WT/m and Chd2m/m mice, along with increased susceptibility to 4-aminopyridine-induced seizures. Transcriptomic analysis identified upregulation of Kcnj11 mRNA in Chd2WT/m and Chd2m/m mice on the 129X1/SvJ background.
Significance:
This mouse model recapitulates key phenotypes observed in CHD2 patients, providing a valuable platform to study the molecular basis and potential treatment strategies for this intractable disorder.
Insights
Researchers developed a mouse model for CHD2 gene mutations, revealing neurodevelopmental and autistic-like features. This model aids in understanding and treating rare neurodevelopmental disorders.
Area of Science:
- Genetics and Neurobiology
- Rare Diseases Research
- Animal Models of Human Disorders
Background:
- Heterozygous loss-of-function mutations in the CHD2 gene are linked to severe neurodevelopmental disorders.
- A lack of accurate animal models hinders research into CHD2-related conditions.
- Chromodomain helicase DNA-binding protein 2 (CHD2) plays a critical role in neurodevelopment.
Purpose of the Study:
- To characterize a novel mouse model for CHD2-related disorders.
- To investigate the neurodevelopmental, behavioral, and electrographic phenotypes associated with Chd2 mutations.
- To establish a platform for studying potential therapeutic strategies.
Main Methods:
- Generation of a frameshift truncating mutation in the mouse Chd2 gene.
- Behavioral analyses including motor function, nest building, and social interaction tests.
- Electrocorticography and transcriptomic analyses to assess brain activity and gene expression.
Main Results:
- Mice with Chd2 mutations on the 129X1/SvJ background exhibited growth retardation and motor deficits.
- Autistic-like behaviors, including impaired nest building and altered social interactions, were observed.
- Increased seizure susceptibility and altered brain oscillations were detected, with Kcnj11 mRNA upregulation.
Conclusions:
- The developed Chd2 mouse model effectively recapitulates key phenotypes of human CHD2 disorders.
- This model provides a valuable tool for investigating the molecular mechanisms underlying CHD2-related neurodevelopmental conditions.
- The model serves as a crucial platform for developing and testing novel treatment strategies.
